201 related articles for article (PubMed ID: 11752083)
1. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
[TBL] [Abstract][Full Text] [Related]
2. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
4. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
5. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
6. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
[TBL] [Abstract][Full Text] [Related]
7. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.
Capello A; Krenning EP; Breeman WA; Bernard BF; de Jong M
J Nucl Med; 2003 Jan; 44(1):98-104. PubMed ID: 12515882
[TBL] [Abstract][Full Text] [Related]
9. The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy.
Slooter GD; Aalbers AG; Breeman WA; Hiemstra CA; Marquet RL; Krenning EP; van Eijck CH
J Nucl Med; 2002 Dec; 43(12):1681-7. PubMed ID: 12468520
[TBL] [Abstract][Full Text] [Related]
10. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
11. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
[TBL] [Abstract][Full Text] [Related]
12. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP
Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040
[TBL] [Abstract][Full Text] [Related]
15. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
16. The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule.
Perico ME; Chinol M; Nacca A; Luison E; Paganelli G; Canevari S
J Nucl Med; 2001 Nov; 42(11):1697-703. PubMed ID: 11696642
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.
Anderson CJ; Jones LA; Bass LA; Sherman EL; McCarthy DW; Cutler PD; Lanahan MV; Cristel ME; Lewis JS; Schwarz SW
J Nucl Med; 1998 Nov; 39(11):1944-51. PubMed ID: 9829587
[TBL] [Abstract][Full Text] [Related]
18. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
Breeman WA; de Jong M; Erion JL; Bugaj JE; Srinivasan A; Bernard BF; Kwekkeboom DJ; Visser TJ; Krenning EP
J Nucl Med; 2002 Dec; 43(12):1650-6. PubMed ID: 12468515
[TBL] [Abstract][Full Text] [Related]
19. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues.
Waser B; Tamma ML; Cescato R; Maecke HR; Reubi JC
J Nucl Med; 2009 Jun; 50(6):936-41. PubMed ID: 19443580
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.
Lewis JS; Lewis MR; Cutler PD; Srinivasan A; Schmidt MA; Schwarz SW; Morris MM; Miller JP; Anderson CJ
Clin Cancer Res; 1999 Nov; 5(11):3608-16. PubMed ID: 10589778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]